- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02065271
Herbal Preparation and Glucose Homeostasis (Herbie)
Rationale: The incidence of obesity and type 2 diabetes (T2D) is increasing rapidly and accounts for a considerable part of health care costs. Herbal supplements are used in many cultures for the prevention and treatment of many different conditions. Due to lack of scientific proof, the application in western cultures are minimal. Animal studies have shown that many constituents of such herbal supplements may have beneficial effects on several important parameters known to be affected in T2D. Still, no scientific proof in humans is available. We therefore aim to investigate the effect of 4-week herbal supplementation on glucose metabolism, lipid metabolism, vascular function and inflammation in subjects with increased fasting glucose levels or a decreased glucose tolerance.
Objective: The primary objectives are to investigate if 4-week herbal supplementation in subjects with increased fasting glucose levels or a decreased glucose tolerance has a positive effect on blood glucose levels and glucose tolerance. The secondary objectives are to investigate if 4-week herbal supplementation in subjects with increased fasting glucose levels or a decreased glucose tolerance has a positive effect on triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) levels, inflammation, adipose tissue and white blood cell gene-expression and AIX both fasted and during an OGTT test.
Study design: This study is a randomized, double-blind, placebo controlled cross-over trial in which two different treatments will be evaluated e.g. an intervention with the herbal mixture and a placebo. Each person will obtain both treatments in random order for four weeks with a wash out period of four weeks in-between. Fasting blood samples will be collected and subjects will receive a OGTT, paralleled by a PWA before and after 4-week supplementation.
Furthermore, after 4-week supplement intake we will collect a urine sample and collect an adipose tissue biopsy. The whole trial will last three months.
Study population: 26 overweight males and females 50-75yrs old with an increased fasting glucose or with an impaired glucose tolerance.
Intervention: Two intervention periods of 4-weeks in which participants will take three times a day a supplement of 500mg herbal or placebo.
Main study parameters/endpoints: Fasting blood glucose levels, glucose tolerance as determined by an oral glucose tolerance test (OGTT), AIX, triglycerides (TG), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) levels, PWA, adipose tissue an white blood cell gene expression and markers of inflammation .
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Subjects that will participate in the study will invest a total of 16.5 hours. Blood collection by vena punctures/insertion of the venflon and the collection of an adipose tissue biopsy can occasionally cause a local hematoma or bruise and some participants may report pain or discomfort. The herbal supplements contain small amounts St. John's wort, which may affect the function of liver enzymes. We will therefore monitor liver function parameters during the supplementation period. Furthermore, subjects are excluded if they use medication known to be affected by St. John's wort. Participant will donate 284ml of blood, dispersed over 12 weeks.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
Gelderland
-
Wageningen, Gelderland, Nederländerna, 6703 HD
- Wageningen University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Males and postmenopausal females For females: menstrual cycle absent for more than 1 year
- age 50-70yrs
- BMI >27 kg/m2
- Increased fasting glucose or an impaired glucose tolerance (two-hour glucose levels >7.8 mmol/L on the 75-g oral glucose tolerance test or fasting glucose >6.1mmol/L).
Exclusion Criteria:
- Systolic blood pressure >160mmHg and diastolic blood pressure> 100mmHg
- Tobacco smoker
- Received inoculations within 2 months of starting the study or planned during the study
- Donated or intend to donate blood from 2 months before the study till months after the study.
- Unstable body weight (weight gain or loss >5kg in the past three months)
- Diagnosed with any long-term medical condition (e.g., diabetes, haemophilia, CVD, anemia, gastrointestinal disease, renal failure, thyroid disorders, cancer, HIV, hepatitis C)
- The use of the following medicine: medicine interfering with St Johns Worth such as, inhibitors of the immune system (ciclosporine, tacrolimus, everolimus, temsirolimus and sirolimus), coumarine type anticoagulant medicine (acenocoumarol and fenprocoumon), anti-epileptica (fenobarbital and fenytoïne), theophylline, atorvastatine, simvastatine, digoxine, kinidine, voriconazol, proton pump inhibitors (omeprazole and esomeprazole) and all anti-depressives ( incl. MAO inhibitors and SSRI's).
- Abuse of drugs/alcohol
- If the participant don't want to sign the informed consent
- If the participant don't want to be informed about unexpected findings during the screening or study
- Participation in another biomedical study
- Additional exclusion criteria for females:
Current use of contraceptives containing hormones Current use of hormone replacement therapy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Crossover tilldelning
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: herbal supplements
500mg, 3 per day, 4weeks
|
|
|
Placebo-jämförare: placebo
500mg, 3 per day, 4 weeks
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
change in glucose tolerance
Tidsram: baseline and after 4-week supplementation
|
by oral glucose tolerance test (OGTT)
|
baseline and after 4-week supplementation
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
change in insulin
Tidsram: baseline and after 4-week supplementation
|
baseline and after 4-week supplementation
|
|
|
change in TAG
Tidsram: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
|
|
change in HbA1c
Tidsram: baseline and after 4 week supplementation
|
glycosylated haemoglobin
|
baseline and after 4 week supplementation
|
|
change in FFA
Tidsram: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
|
|
change in cholesterol
Tidsram: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
change in vascular function
Tidsram: baseline and after 4-week supplementation
|
by pulse wave analysis (PWA)
|
baseline and after 4-week supplementation
|
|
change in ALAT/ASAT
Tidsram: baseline and after 4 week supplementation
|
baseline and after 4 week supplementation
|
|
|
Urinary metabolites
Tidsram: after 4 week supplementation
|
after 4 week supplementation
|
|
|
adipose tissue gene expression
Tidsram: after 4 week supplementation
|
by qpcr
|
after 4 week supplementation
|
|
change in markers of inflammation
Tidsram: baseline and after 4 week of supplementation
|
by PBMC genexpression and plasma cytokines
|
baseline and after 4 week of supplementation
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Lydia A Afman, PhD, Wageningen University
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- NL44919.081.13
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Inflammation
-
Center for Research and Innovation Viña Concha...Universidad Católica del MauleHar inte rekryterat ännuInflammerande | Antioxidantstatus, inflammation | Biomarkörer för inflammation | Antioxidantegenskaper | Kardiometaboliska hälsoindikatorerChile
-
University of NebraskaHar inte rekryterat ännuParodontal inflammationFörenta staterna
-
Oral Science International Inc.AdvarraHar inte rekryterat ännu
-
University of NebraskaAvslutadParodontal inflammationFörenta staterna
-
University of California, DavisAvslutadPostprandial inflammationFörenta staterna
-
Probi ABLund UniversityAvslutadLåggradig inflammation | Increased Intestinal PermeabilitySverige
-
Loughborough UniversityAvslutadTräningsutlöst inflammationStorbritannien
-
Alcon ResearchIndragenPostkirurgisk inflammation
-
Ahmad ElheenyAktiv, inte rekryterande
-
Pamukkale UniversityAvslutadParodontal inflammationKalkon
Kliniska prövningar på herbal supplement
-
Hamdard UniversityAvslutad
-
Hong Kong Baptist UniversityRekrytering
-
NYU Langone HealthRekrytering
-
Baylor College of MedicineThe University of Texas Health Science Center, Houston; University of Oklahoma och andra samarbetspartnersAvslutadBronkopulmonell dysplasiFörenta staterna, Österrike
-
Irish Response t/a Lifes2goodStephens & Associates, Inc.AvslutadHårförtunningFörenta staterna
-
University of ThessalyRekryteringMultipel skleros | Anemi | IBD | Kolit Ulcerös | Hypertoni (HTN)Grekland
-
Central Arkansas Veterans Healthcare SystemUniversity of ArkansasAvslutadSarkopeni | ImmunosenescensFörenta staterna
-
Codex Labs CorporationEurofins Dermscan PharmascanAktiv, inte rekryterande
-
Universidad de GranadaRekrytering
-
Fujian Cancer HospitalHar inte rekryterat ännu